Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Treatment Discovered for Osteoporosis

By Drug Discovery Trends Editor | November 21, 2013

University of Sydney researchers have discovered a promising treatment for osteoporosis, which is easily delivered in water soluble form.
 
After more than four years of investigation, researchers from the Aging Bone Research Program (Sydney Medical School’s Nepean campus), have found the treatment has shown very promising results in animal experiments.
 
The compound is called picolinic acid, a product derived of the essential amino acid tryptophan.
 
Lead researcher Professor Gustavo Duque said the odorless compound can be easily dissolved in water.
 
“This is a major step in the development of a completely new type of medication for osteoporosis. Instead of stopping bone destruction, our compound instead stimulates bone formation,” he said. “The product is easily dissolved in water, has a higher level of absorption and did not induce any side effects in the treated mice. When this medication was administered in the water of normal and menopausal mice, picolinic acid strongly and safely increased bone mass in normal mice and rescued bone from menopause-associated osteoporosis.”
 
Duque said the team had patented the compound and will expand their trials to humans in the near future in a bid to address the increasing numbers of people developing the condition.
 
“Osteoporosis affects an estimated 300 million people worldwide. One in three women over 50 will experience osteoporotic fractures, as will one in five men. Despite the current treatments available, by 2050, the worldwide incidence of hip fracture in men is projected to increase by 310 percent and 240 percent in women,” he said. “This increase is explained by the low rate of diagnosis and treatment for osteoporosis, as well as some concerns about the potential side effects of the current treatments. There are also close similarities between the majority of the osteoporosis medications in terms of their anti-fracture effect and mechanism of action.”
 
According to Duque, there is a reduction in bone formation as part of the aging process that predisposes people to osteoporosis.
 
“In this case we are targeting the real problem by stimulating the bone forming cells to work and produce more bone, thus increasing bone mass and hopefully preventing new fractures,” he said.
 
Source: University of Sydney
 

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE